Welcome to AiCuris: The Powerhouse for Anti-infectives    


“Committed to making the difference”

AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).

Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.

AiCuris Provides Corporate Update

AiCuris Anti-infective Cures GmbH today provided a strategic update, outlining its recent achievements and plans for future growth.
  • Over 15,000 patients worldwide already treated with Letermovir to prevent Cytomegalovirus (CMV) infection and disease in allogeneic stem cell transplantation
  • Pritelivir in Phase 2 testing for treatment of Acyclovir resistant HSV infections in immune-comprised patients; AiCuris is preparing a pivotal Phase 3 trial
  • AIC649, a potential cure for chronic hepatitis B, to be partnered
  • Company fully dedicated to develop novel antibiotics to combat antimicrobial resistance
  • Significant ongoing revenue stream provides funding to carry out ambitious plans

Read more ...

AiCuris to Attend BIO-Europe® 2019

AiCuris will be present at the BIO-Europe 2019 partnering conference taking place from November 11th – 13th in Hamburg, Germany.

 As part of the conference, CEO Dr. Holger Zimmermann will participate in the panel entitled “Workable business models for AMR innovation” on Monday, November 11th.

Read more ...

PREVYMIS® @ Deutsches Museum

Letermovir project by AiCuris becomes part of the permanent exhibition of Deutsches Museum in Munich

The Letermovir project, which was awarded the German Future Prize 2018, will be on public display for the next ten years at the Deutsches Museum.
The winners, Prof. Dr. Helga Rübsamen-Schaeff, founding CEO, and Dr. Holger Zimmermann, CEO of AiCuris Anti-Infective Cures GmbH, unveiled the module yesterday at a festive event.

Read more ...